drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CMV-specific T cells genetically engineered to express an anti-CD19 chimeric antigen receptor, enabling targeted cytotoxicity against CD19-positive malignant B cells; endogenous CMV-specific TCRs allow antigen-driven recall responses to support in vivo expansion and persistence after transplant.
nci_thesaurus_concept_id
C187649
nci_thesaurus_preferred_term
Anti-CD19-CAR CMV-specific T-lymphocytes
nci_thesaurus_definition
A preparation of human cytomegalovirus (CMV)-specific T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-CAR CMV-specific T-lymphocytes recognize, bind to, and induce selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The anti-CD19-CAR CMV-specific T-lymphocytes may potentially be expanded in vivo through CMV vaccination.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CMV-specific T cells engineered to express an anti-CD19 chimeric antigen receptor that redirects T-cell cytotoxicity to CD19-positive malignant B cells; native CMV-specific TCRs enable antigen-driven recall responses to enhance in vivo expansion and persistence, which can be boosted by CMV vaccination post-transplant.
drug_name
Anti-CD19-CAR CMV-specific T-lymphocytes
nct_id_drug_ref
NCT05432635